Celltrion

Sandoz axes filing of US Rituxan biosimilar

https://pharmaphorum.com/news/sandoz-axes-filing-of-us-rituxan-biosimilar/

Celltrion/Teva Rituxan biosimilar edges closer to US approval

https://pharmaphorum.com/news/celltrion-teva-rituxan-biosimilar-edges-closer-to-us-approval/

Celltrion’s Rituxan biosimilar gets glowing review ahead of key meeting

https://pharmaphorum.com/news/celltrions-rituxan-biosimilar-gets-glowing-review-ahead-of-key-meeting/

Biosimilars underused in rheumatoid arthritis on the NHS – experts

https://pharmaphorum.com/news/biosimilars-underused-rheumatoid-arthritis-nhs-experts/

Celltrion hopes to outdo inflammatory disease rivals with SC infliximab

https://pharmaphorum.com/news/celltrion-hopes-to-outdo-inflammatory-disease-rivals-with-sc-infliximab/

FDA rejects Teva/Celltrion biosimilars

https://pharmaphorum.com/news/fda-rejects-teva-celltrion-biosimilars/

Mundipharma to market Herceptin biosimilar in key EU markets

https://pharmaphorum.com/news/mundipharma-market-celltrion-cancer-biosimilar-key-eu-markets/

Its Herceptin biosimilar nearing launch, Celltrion begins work on Keytruda copy

https://pharmaphorum.com/news/herceptin-biosimilar-nearing-launch-celltrion-begins-work-keytruda-copy/

Pfizer’s rituximab biosimilar gets late-stage trial boost

https://pharmaphorum.com/news/pfizers-rituximab-biosimilar-succeeds-phase-3-trial/

1 2

Close in 10 seconds

Pharmaphorum.com

Search